home · filing · 0001679363-24-000004
8-K
filed January 3, 2024, 6:59 PM ET
CIK 0001679363
leadership
confidence high
sentiment neutral
materiality 0.60
CEO Praveen Tipirneni returns from medical leave, resumes role effective Jan 2, 2024
Morphic Holding, Inc.
Dr. Tipirneni resumed day-to-day operational responsibilities as CEO and principal executive officer.
Bruce Rogers stepped down as interim principal executive officer, remains President of Morphic.
Tipirneni will present at the 42nd Annual J.P. Morgan Healthcare Conference on Jan 10, 2024.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Effective 2024-01-02
Successor Praveen Tipirneni
Filed January 3, 2024, 6:59 PM ET
Bruce N. Rogers, Ph.D., the Company’s President, is no longer the Company’s interim principal executive officer.
Role change
Praveen Tipirneni
Chief Executive Officer
Morphic Holding, Inc.
Effective 2024-01-02
Filed January 3, 2024, 6:59 PM ET
Effective as of January 2, 2024, Dr. Tipirneni has resumed his day-to-day operational responsibilities at the Company.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Bruce N. Rogers changed role as interim principal executive officer at Morphic Holding, Inc..
Action is no longer
Role interim principal executive officer
Exact text from the filing
Bruce N. Rogers, Ph.D., the Company’s President, is no longer the Company’s interim principal executive officer.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Praveen Tipirneni changed role as Chief Executive Officer at Morphic Holding, Inc..
Action resumed
Role Chief Executive Officer
Exact text from the filing
Effective as of January 2, 2024, Dr. Tipirneni has resumed his day-to-day operational responsibilities at the Company.
View on SEC.gov
Source: SEC EDGAR
accession 0001679363-24-000004
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.